Expanding access to precision medicine with innovations in drug development and diagnostics

Key Takeaways 

• While tissue-based biopsy has been the gold standard, plasma- and liquid-based modalities can provide critical value, especially when tissue is limited or unavailable
• Despite the benefits of a combined approach that uses both tissue and liquid biopsy, the biggest challenges lie in coverage and reimbursement
• From geographic location to in-house vs. outsourced testing, several factors must be taken into account when considering a companion diagnostic approach

Key Discussion Points

• Value of liquid-based approaches in both drug discovery and diagnostics
• Market access challenges for liquid biopsy-based approaches
• CDx development considerations